[go: up one dir, main page]

MXPA02005626A - Composiciones para el tratamiento de filtracion glomerular, conductos arteriosos y osteoporosis del paciente. - Google Patents

Composiciones para el tratamiento de filtracion glomerular, conductos arteriosos y osteoporosis del paciente.

Info

Publication number
MXPA02005626A
MXPA02005626A MXPA02005626A MXPA02005626A MXPA02005626A MX PA02005626 A MXPA02005626 A MX PA02005626A MX PA02005626 A MXPA02005626 A MX PA02005626A MX PA02005626 A MXPA02005626 A MX PA02005626A MX PA02005626 A MXPA02005626 A MX PA02005626A
Authority
MX
Mexico
Prior art keywords
osteoporosis
ductus arteriosus
compositions
glomerular filtration
patent ductus
Prior art date
Application number
MXPA02005626A
Other languages
English (en)
Inventor
Krishna G Peri
Original Assignee
Pital Sainte Justine H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pital Sainte Justine H filed Critical Pital Sainte Justine H
Publication of MXPA02005626A publication Critical patent/MXPA02005626A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Flanged Joints, Insulating Joints, And Other Joints (AREA)
  • Joints With Sleeves (AREA)
  • Pipe Accessories (AREA)
  • Water Treatment By Sorption (AREA)
  • Water Treatment By Electricity Or Magnetism (AREA)

Abstract

La presente invencion se refiere a una composicion de una materia que comprende antagonistas novedosos del receptor de prostaglandina E2, y su uso en tratamientos para regular la filtracion de fluidos en el rinon, evitando la perdida mineral de los huesos en la osteoporosis y la enfermedad dental y adicionalmente, el cierre de los conductos arteriosos (DA) en infantes prematuros o animales fetales. Adicionalmente, las composiciones incluyen peptidos lineales, analogos peptidos, y peptidomimeticos.
MXPA02005626A 1999-12-06 2000-12-06 Composiciones para el tratamiento de filtracion glomerular, conductos arteriosos y osteoporosis del paciente. MXPA02005626A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45548399A 1999-12-06 1999-12-06
PCT/CA2000/001445 WO2001042281A1 (en) 1999-12-06 2000-12-06 Compositions for treating abnormalities in glomerular filtration, patent ductus arteriosus and osteoporosis

Publications (1)

Publication Number Publication Date
MXPA02005626A true MXPA02005626A (es) 2004-09-10

Family

ID=23808998

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02005626A MXPA02005626A (es) 1999-12-06 2000-12-06 Composiciones para el tratamiento de filtracion glomerular, conductos arteriosos y osteoporosis del paciente.

Country Status (12)

Country Link
US (1) US7442763B2 (es)
EP (1) EP1244693B1 (es)
JP (1) JP2003516417A (es)
AT (1) ATE298346T1 (es)
AU (1) AU784630B2 (es)
CA (1) CA2396739A1 (es)
DE (1) DE60020997T2 (es)
ES (1) ES2246915T3 (es)
MX (1) MXPA02005626A (es)
NZ (1) NZ520762A (es)
WO (1) WO2001042281A1 (es)
ZA (1) ZA200205795B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040235749A1 (en) * 1999-09-15 2004-11-25 Sylvain Chemtob G-protein coupled receptor antagonists
DE60020997T2 (de) 1999-12-06 2006-05-24 Hopital Sainte-Justine, Montreal Verbindungen zur Behandlung von abnormaler Glomerulusfiltration, Ductus arteriosus apertus und Osteoporose
EP1467738A1 (en) * 2001-10-08 2004-10-20 Medical Research Council Use of prostaglandin e synthase inhibitors, or ep2 or ep4 receptor antagonists, in the treatment of a pathological condition of the uterus
JP2005511562A (ja) * 2001-10-31 2005-04-28 メディカル リサーチ カウンシル 月経困難症及び月経過多の治療のためのプロスタグランジンレセプターｅｐ２及び／又はｅｐ４のアンタゴニスト
US7414029B2 (en) 2002-05-23 2008-08-19 Theratechnologies, Inc. Antagonistic peptides of prostaglandin E2 receptor subtype EP4
AU2003233297A1 (en) * 2002-05-23 2003-12-12 Theratechnologies Inc Antagonistic peptides of prostaglandin e2 receptor subtype ep4
EP1878741A3 (en) * 2002-05-23 2008-02-20 Theratechnologies Inc. Antagonistic peptides of prostaglandin E2 receptor subtype EP4
WO2004073589A2 (en) * 2003-02-24 2004-09-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor prostaglandin e2 ep4 (prostaglandin e2 ep4)
US8618054B2 (en) * 2004-05-05 2013-12-31 Valorisation-Rechereche Société en Commandite Interleukin-1 receptor antagonists, compositions, and methods of treatment
EP2846793A1 (en) 2012-05-09 2015-03-18 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods and pharmaceutical compositions for prevention or treatment of chronic obstructive pulmonary disease
AU2022238571A1 (en) 2021-03-18 2023-09-14 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9019120D0 (en) * 1990-09-01 1990-10-17 Beecham Group Plc Novel compounds
WO1994005695A1 (en) 1992-09-10 1994-03-17 New York University Polypeptides of g-coupled receptor proteins, and compositions and methods thereof
WO1994020127A1 (en) * 1993-03-05 1994-09-15 Cytel Corporation Hla-a2.1 binding peptides and their uses
US5869281A (en) 1993-06-25 1999-02-09 Merck Frosst Canada Inc. DNA encoding prostaglandin receptor FP
US5605814A (en) 1993-08-31 1997-02-25 Merck Frosst Canada Inc. DNA encoding human prostaglandin receptor EP2
EP0730660A4 (en) * 1993-10-29 1998-02-25 Incyte Pharma Inc CHIMEAN PROTEINE PROTEASE NEXIN-1 CONTAINING VARIANTS
WO1995029193A2 (en) * 1994-04-22 1995-11-02 The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services Melanoma antigens
US5866679A (en) * 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
WO1996006856A1 (en) * 1994-08-31 1996-03-07 Robert Webber Dopamine receptor peptides and anti-peptide antibodies
ES2244966T3 (es) * 1994-12-12 2005-12-16 Omeros Corporation Solucion de irrigacion y su utilizacion para inhibir perioperatoriamente el dolor, la inflamacion y el espasmo en una herida.
CA2211176A1 (en) 1995-01-25 1996-08-01 Cor Therapeutics, Inc. Recombinant c140 receptor, its agonists and antagonists, and nucleic acids encoding the receptor
US5877155A (en) * 1995-03-17 1999-03-02 The Research Foundation Of State University Of New York Mimotopes and anti-mimotopes of human platelet glycoprotein Ib/IX
US6117839A (en) * 1995-06-07 2000-09-12 Gensci Regeneration Sciences, Inc. Bone stimulating factor
AU2658897A (en) * 1996-03-21 1997-10-10 Epimmune, Inc. Hla-a2.1 binding peptides and their uses
EP0926955A4 (en) * 1996-09-12 2003-05-07 Merck & Co Inc Conjugates useful in the treatment of prostate cancer
US5955575A (en) 1997-12-22 1999-09-21 Hopital Sainte-Justine Antagonists of G-protein-coupled receptor
AUPP320998A0 (en) * 1998-04-27 1998-05-21 Walter And Eliza Hall Institute Of Medical Research, The Tyrosine phosphatase IA-2 T-cell epitopes
US6984719B1 (en) 1998-09-17 2006-01-10 Hospital Sainte-Justine Peptide antagonists of prostaglandin F2α receptor
US20040235749A1 (en) 1999-09-15 2004-11-25 Sylvain Chemtob G-protein coupled receptor antagonists
DE60020997T2 (de) 1999-12-06 2006-05-24 Hopital Sainte-Justine, Montreal Verbindungen zur Behandlung von abnormaler Glomerulusfiltration, Ductus arteriosus apertus und Osteoporose

Also Published As

Publication number Publication date
EP1244693A1 (en) 2002-10-02
DE60020997T2 (de) 2006-05-24
DE60020997D1 (de) 2005-07-28
JP2003516417A (ja) 2003-05-13
CA2396739A1 (en) 2001-06-14
WO2001042281A1 (en) 2001-06-14
ZA200205795B (en) 2007-01-31
ATE298346T1 (de) 2005-07-15
AU2134001A (en) 2001-06-18
AU784630B2 (en) 2006-05-18
EP1244693B1 (en) 2005-06-22
ES2246915T3 (es) 2006-03-01
US7442763B2 (en) 2008-10-28
US20030017988A1 (en) 2003-01-23
NZ520762A (en) 2005-02-25

Similar Documents

Publication Publication Date Title
MXPA02005626A (es) Composiciones para el tratamiento de filtracion glomerular, conductos arteriosos y osteoporosis del paciente.
KR101956579B1 (ko) 상아질 지각과민증 완화를 위한 치약 조성물
CA2429850A1 (en) Ep4 receptor selective agonists in the treatment of osteoporosis
AP2001002357A0 (en) EP4 receptor selective agonists in the treatment of osteoporosis.
BR0107613A (pt) Bloqueio do crescimento de axÈnios mediado por receptor nogo
EP1484339A3 (en) Kallikrein-inhibiting "Kunitz Domain" proteins and nucleic acids encoding the same
YU18400A (sh) Prostaglanidin agonisti i njihova primena za tretiranje koštanih poremećaja
DK0664133T3 (da) "Ostim Apatit"-præparat til stimulering af vækst i knoglevæv
EP0881908A4 (en) USE OF FIBROBLAST GROWTH FACTORS FOR STIMULATING BONE GROWTH
PL329526A1 (en) Casein peptide containing tooth-cleaning composition of long shelf-life
EP0950417A3 (en) Treatment of skeletal disorders
TNSN98104A1 (fr) Agonistes de prostaglandines, procede pour leur preparation et compositions pharmaceutiques les contenant.
PT2009025E (pt) Método de inibição da actividade dos osteoclastos
ATE469217T1 (de) Den phosphorsäure-metabolismus, den kalzium- metabolismus, verkalkung und den vitamin d- metabolismus kontrollierende polypeptide sowie für diese kodierende dna-moleküle
GB0110430D0 (en) Protein variants and uses thereof
BR112019018871A2 (pt) complexos para tratar sensibilidade
KR20210139321A (ko) 광화를 촉진하기 위한 조성물 및 방법
AU5548801A (en) Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
DE02748548T1 (de) Calcium-l-threonat zur prävention oder behandlung von knochenfrakturen
AU2003251729A8 (en) Use of antibodies against flt-1 for the treatment of osteoporosis
TR200102655T2 (tr) Dört L. infantum proteininin antijen belirleyicilerini kodlayan kimerik gen.
PL353065A1 (en) Novel polypeptide and dna thereof
BRPI0412477A (pt) aperfeiçoados polipeptìdeos de interferon-beta-1b recombinantes humanos
Iizuka et al. Chemical alteration by tooth bleaching of human salivary proteins that infiltrated subsurface enamel lesions—Experimental study with bovine lesion model systems—
JP2008074773A (ja) 口腔用組成物